p38 MAP Kinase ProgramValidates ArQule Drug Discovery Approach
Demonstrated the utility of ArQule’s chemoinformatics, AMAP and ADME platform
Resulted in multiple lead series for optimization
Strong animal data used to advance several lead compounds to pilot toxicology
Oct 16 - Nominated one Optimal Chemical EntityTM, ARQ 101, for GLP-tox studies to start by year end